Investigating the effect of ondansetron on Levodopa-induced dyskinesia in patients with parkinson's disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190427043389N5

Enrollment

Registered

2023-12-11

Start date

2023-12-21

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

levodopa-induced dyskinesia. Neuroleptic induced parkinsonism

Interventions

Intervention 1: Intervention group: will take ondansetron tablets in the form of 8 mg daily orally in the first week and then in the form of 12 mg daily (8 mg in the morning and 4 mg at night) from th

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients with Parkinson's disease stages 3, and 4 based on Hoehn and Yahr scale age over 18 years patients with levodpa induced dyskinesia Patient satisfaction

Exclusion criteria

Exclusion criteria: Allergy to ondansetron (rash, itching) Concomitant use of apomorphine in patients with off episodes pregnancy breastfeeding The patient's unwillingness for participation

Design outcomes

Primary

Measure	Time frame
Levodopa induced dyskinesia score in Unified Dyskinesia Rating Scale questionnare. Timepoint: Before intervention, one and two months after starting intervention. Method of measurement: Unified Dyskinesia Rating Scale questionnare.	—

Secondary

Measure	Time frame
Levodopa-induced dyskinesia 's severity. Timepoint: Before starting intervention, one and two months after starting intervention. Method of measurement: Unified Dyskinesia Rating Scale questionnare.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamed Ghavimi

Zanjan University of Medical Sciences

Hamed.ghavimi@gmail.com0098 24 334736354

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026